Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Recommendation of “Hold” from Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been assigned an average rating of “Hold” from the six research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.3333.

AUTL has been the topic of a number of research analyst reports. Zacks Research downgraded Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Needham & Company LLC decreased their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, January 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently bought and sold shares of the company. Invesco Ltd. boosted its position in Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Autolus Therapeutics by 809.4% in the first quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after buying an additional 91,222 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Autolus Therapeutics by 63.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock valued at $69,000 after buying an additional 11,821 shares during the period. Delaney Dennis R purchased a new stake in Autolus Therapeutics during the second quarter valued at approximately $55,000. Finally, Aubrey Capital Management Ltd raised its position in Autolus Therapeutics by 276.8% in the second quarter. Aubrey Capital Management Ltd now owns 452,200 shares of the company’s stock worth $1,045,000 after acquiring an additional 332,202 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL opened at $1.40 on Friday. The company has a market cap of $372.60 million, a PE ratio of -1.69 and a beta of 1.98. The firm’s 50 day moving average price is $1.58 and its 200-day moving average price is $1.60. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). The firm had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. On average, analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.